Cytogen Inc (217330) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytogen Inc (217330) has a cash flow conversion efficiency ratio of -0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.13 Billion ≈ $-1.44 Million USD) by net assets (₩35.99 Billion ≈ $24.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cytogen Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Cytogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cytogen Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Cytogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raisio Oyj
HE:RAIKV
|
0.029x |
|
Hainan Airlines Co Ltd B
SHG:900945
|
1.672x |
|
Y-Entec Co. Ltd
KQ:067900
|
0.018x |
|
Intech Biopharm Ltd
TWO:6461
|
-0.125x |
|
EPE Capital Partners Ltd
JSE:EPE
|
0.002x |
|
Lion Selection Group Ltd
AU:LSX
|
-0.007x |
|
Cameo Communications Inc
TW:6142
|
-0.032x |
|
ÖKOWORLD AG
XETRA:VVV3
|
0.008x |
Annual Cash Flow Conversion Efficiency for Cytogen Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Cytogen Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see 217330 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩35.99 Billion ≈ $24.39 Million |
₩-6.95 Billion ≈ $-4.71 Million |
-0.193x | +1.50% |
| 2024-12-31 | ₩48.58 Billion ≈ $32.92 Million |
₩-9.53 Billion ≈ $-6.46 Million |
-0.196x | -37.81% |
| 2023-12-31 | ₩53.36 Billion ≈ $36.16 Million |
₩-7.59 Billion ≈ $-5.15 Million |
-0.142x | +87.38% |
| 2022-12-31 | ₩5.66 Billion ≈ $3.83 Million |
₩-6.38 Billion ≈ $-4.32 Million |
-1.128x | -396.17% |
| 2021-12-31 | ₩23.01 Billion ≈ $15.59 Million |
₩-5.23 Billion ≈ $-3.54 Million |
-0.227x | +6.68% |
| 2020-12-31 | ₩18.34 Billion ≈ $12.43 Million |
₩-4.47 Billion ≈ $-3.03 Million |
-0.244x | -29.58% |
| 2019-12-31 | ₩17.92 Billion ≈ $12.14 Million |
₩-3.37 Billion ≈ $-2.28 Million |
-0.188x | -49.56% |
| 2018-12-31 | ₩22.04 Billion ≈ $14.94 Million |
₩-2.77 Billion ≈ $-1.88 Million |
-0.126x | +72.70% |
| 2017-12-31 | ₩4.73 Billion ≈ $3.21 Million |
₩-2.18 Billion ≈ $-1.48 Million |
-0.460x | +90.73% |
| 2016-12-31 | ₩475.51 Million ≈ $322.25K |
₩-2.36 Billion ≈ $-1.60 Million |
-4.969x | -551.88% |
| 2015-12-31 | ₩2.66 Billion ≈ $1.80 Million |
₩-2.03 Billion ≈ $-1.37 Million |
-0.762x | +64.00% |
| 2014-12-31 | ₩484.59 Million ≈ $328.40K |
₩-1.03 Billion ≈ $-695.41K |
-2.118x | -- |
About Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more